India, June 11 -- Telix Pharmaceuticals Limited (TLX,TLX.AX) announces that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is now commercially available nationally in the United States.
Gozellix is available through Telix's comprehensive network of distribution partners, Cardinal Health, Inc., PharmaLogic Holdings Corp., Jubilant Radiopharma, and RLS Radiopharmacies.
After radiolabelling with 68Ga, Gozellix is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, and those with suspected biochemical recurrence (BCR) based on elevated serum ...